Navigation Links
Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
Date:4/9/2008

elf as a leader in the development and commercialization of novel RNAi therapeutics," said Mohammad Azab, M.D., president and chief executive officer of Intradigm. "We have established an impressive IP portfolio that spans the areas of siRNA structure and sequence, as well as RNAi delivery, providing us a distinct competitive advantage enjoyed by very few other companies."

"We are keenly aware of the critical role that the fundamental RNAi research being conducted in our labs may play in ultimately bringing novel RNAi therapeutics to patients who desperately need them," stated James P. McNamara, Ph.D., Executive Director of the Office of Technology Management at the University of Massachusetts Medical School. "For this reason, we are driven to align with leaders in the RNAi therapeutic space, such as Intradigm, to provide them access to our intellectual property and support their important drug development efforts. We are eager to witness Intradigm's progress and excited at that prospect of our IP playing a central role in the company's future success."

ABOUT THE RNAi NANOPLEX DELIVERY TECHNOLOGY

To address the issue of effective and targeted delivery of RNAi therapeutics, Intradigm has developed and in-licensed an extensive intellectual property portfolio around its proprietary RNAi Nanoplex (NPX) delivery technology. The RNAi NPX delivery technology is a modular, multi-component delivery vector that carries active siRNA molecules in its core with the flexibility to attach a Polyethylene Glycol (PEG) layer and/or a targeting ligand to the polymer-siRNA NPX to improve circulation half life and achieve selective distribution to the target tissue. At the core of the RNAi NPX delivery technology is Intradigm's proprietary peptide-based biodegradable polymer known as PolyTran(TM). PolyTran enables safe systemic delivery of the siRNAs. Additionally, this platform is unique in its ability to offer tissue specific targeting of siRNA through the attachm
'/>"/>

SOURCE Intradigm Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
3. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
4. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
5. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
6. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
7. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
8. Syngenta Licenses Chromatin Gene Stacking Technology
9. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
10. Prometheus Licenses COLAL-PRED(R) From Alizyme
11. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 In ... resources that help them drive positive health outcomes, ... vital source of patient care in their communities. ... annual tradeshow and conference, AmerisourceBergen announced a new ... Pharmacy Services Administration Organization and help independent pharmacies ...
(Date:7/31/2015)... Dallas, Texas (PRWEB) , ... July 31, 2015 ... ... research report, offering competitive market analysis and premium industry insights on the global ... challenges, based on a collective study of vivid market scenarios and analysis of ...
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to ... hydrolyzed gluten in foods, has been accepted by AOAC International as Official First ... in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... and Industry Experience to ... ... ), a,leading, global full-service clinical research organization, today,announced the reappointment of ... was Executive Vice President and,Chief Financial Officer for Kendle from 1996 ...
... To Discuss the Data and Ongoing ... Clinical Development Programs, RICHMOND, Calif., Nov. ... data from its,SB-509-601 clinical trial, one of Sangamo,s three Phase 2 ... (DN). The data demonstrate that repeat administration of the,drug is well ...
... generation and improved HDL functionality are distinguishing ... NEW ORLEANS, LA, Nov. 10 /PRNewswire-FirstCall/ ... announce today key scientific data,was presented in ... of,RVX-208 at the American Heart Association Scientific ...
Cached Biology Technology:Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors 2Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6RVX-208 Data Demonstrates Increase in Functional HDL Particles 2RVX-208 Data Demonstrates Increase in Functional HDL Particles 3RVX-208 Data Demonstrates Increase in Functional HDL Particles 4
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... G&D, Dr. Guillermo Oliver (St. Jude Childrens ... resolve a century-old debate over the origin of ... the lymphatic vasculature is integral to understanding its ... tissue fluid levels) and disease (lymphedema and spreading ...
... of the scientific journal Science presents research on the ... that ultimately may lead to better diagnosis and treatment ... people every year. It may also bring an ... Giardia lamblia is an intestinal parasite that exists all ...
... Standards and Technology (NIST) today announced 56 ... development projects under the agencys Advanced Technology ... a broad range of technologies, including medical ... electronics, transportation, nanotechnology, energy conservation and automated ...
Cached Biology News:New Swedish research hope for millions of sufferers 2
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: